<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01464879</url>
  </required_header>
  <id_info>
    <org_study_id>000024</org_study_id>
    <nct_id>NCT01464879</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Evaluate the Pharmacokinetics of Testosterone Gel Using an Applicator</brief_title>
  <official_title>A Phase 2, Open-Label, Sequential Dose Escalation Study in Adult Hypogonadal Males to Evaluate the Pharmacokinetics of Three Volumes of FE 999303 (Testosterone Gel), Applied to the Shoulder/Upper Arm, Using an Applicator Compared With Hand Application</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2 clinical trial in adult hypogonadal males with baseline morning serum
      testosterone concentrations &lt;300 ng/dL. The purpose of this study is to evaluate the
      pharmacokinetics of FE 999303, delivered using an applicator in comparison to hand
      application
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Responder Rate: Percentage of Subjects Whose Average Steady State Concentration (Cavg) of Serum Total Testosterone Levels Are Between 300 and 1050 ng/dL Following Treatment With Each of Three Volumes of FE 999303 Applied With an Applicator.</measure>
    <time_frame>Days 15-21, Days 22-28 &amp; Days 29-35</time_frame>
    <description>Descriptive statistics was used to present the outcome results.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Responder Rate: Percentage of Subjects Whose Cavg Serum Total Testosterone Levels Are Between 300 and 1050 ng/dL Following Treatment With One Volume of FE 999303 Applied by Hand.</measure>
    <time_frame>Days 1-7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Total Testosterone and DHT (Dihydrotestosterone) Measuring Area Under the Concentration-time Curve From the Last Dose and 24 Hrs. Post Dose (AUCτ)</measure>
    <time_frame>Samples were collected pre-dose and at 2, 4, 6, 8, 10, 12, and 24 hr post-dose on Day 21, Day 28 &amp; Day 35 of testosterone gel application through applicator</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Total Testosterone and DHT Measuring Time of Maximum Observed Concentration (Tmax)</measure>
    <time_frame>Samples were collected pre-dose and at 2, 4, 6, 8, 10, 12, and 24 hr post-dose on Day 21, Day 28 &amp; Day 35 of testosterone gel application through applicator</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Total Testosterone and DHT Measuring Maximum Concentration Observed (Cmax)</measure>
    <time_frame>Samples were collected pre-dose and at 2, 4, 6, 8, 10, 12, and 24 hr post-dose on Day 21, Day 28 &amp; Day 35 of testosterone gel application through applicator</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Total Testosterone and DHT Measuring Cavg</measure>
    <time_frame>Samples were collected pre-dose and at 2, 4, 6, 8, 10, 12, and 24 hr post-dose on Day 21, Day 28 &amp; Day 35 of testosterone gel application through applicator</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Total Testosterone and DHT Measuring Minimum Concentration Observed (Cmin)</measure>
    <time_frame>Samples were collected pre-dose and at 2, 4, 6, 8, 10, 12, and 24 hr post-dose on Day 21, Day 28 &amp; Day 35 of testosterone gel application through applicator</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Total Testosterone and DHT Measuring Time of Minimum Observed Concentration (Tmin)</measure>
    <time_frame>Samples were collected pre-dose and at 2, 4, 6, 8, 10, 12, and 24 hr post-dose on Day 21, Day 28 &amp; Day 35 of testosterone gel application through applicator</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Total Testosterone and DHT Measuring AUCτ</measure>
    <time_frame>Samples were collected pre-dose and at 2, 4, 6, 8, 10, 12, and 24 hr post-dose on Day 7 of testosterone gel application through hand</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Total Testosterone and DHT Measuring Tmax</measure>
    <time_frame>Samples were collected pre-dose and at 2, 4, 6, 8, 10, 12, and 24 hr post-dose on Day 7 of testosterone gel application through hand</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Total Testosterone and DHT Measuring Cmax</measure>
    <time_frame>Samples were collected pre-dose and at 2, 4, 6, 8, 10, 12, and 24 hr post-dose on Day 7 of testosterone gel application through hand</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Total Testosterone and DHT Measuring Cavg</measure>
    <time_frame>Samples were collected pre-dose and at 2, 4, 6, 8, 10, 12, and 24 hr post-dose on Day 7 of testosterone gel application through hand</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Total Testosterone and DHT Measuring Cmin</measure>
    <time_frame>Samples were collected pre-dose and at 2, 4, 6, 8, 10, 12, and 24 hr post-dose on Day 7 of testosterone gel application through hand</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Total Testosterone and DHT Measuring Tmin</measure>
    <time_frame>Samples were collected pre-dose and at 2, 4, 6, 8, 10, 12, and 24 hr post-dose on Day 7 of testosterone gel application through hand</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Hypogonadal Males</condition>
  <arm_group>
    <arm_group_label>Testosterone 2.50 mL (hand)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm self-applied two strokes (2.50 mL) of testosterone gel by hand, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm every day for seven days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Testosterone 1.25 mL (applicator)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm self-applied one stroke (1.25 mL) of testosterone gel by applicator to the shoulder/upper arm every day for seven days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Testosterone 2.50 mL (applicator)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm self-applied two strokes (2.50 mL) of testosterone gel by applicator, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm every day for seven days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Testosterone 3.75 mL (applicator)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm self-applied three strokes (3.75 mL) of testosterone gel by applicator, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm and a third stroke to the first shoulder/upper arm, every day for seven days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone Gel (FE 999303)</intervention_name>
    <arm_group_label>Testosterone 2.50 mL (hand)</arm_group_label>
    <arm_group_label>Testosterone 1.25 mL (applicator)</arm_group_label>
    <arm_group_label>Testosterone 2.50 mL (applicator)</arm_group_label>
    <arm_group_label>Testosterone 3.75 mL (applicator)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 18-75

          -  History of hypogonadism

          -  In good health based on medical history, physical examination, and clinical laboratory
             tests

          -  Serum testosterone deficiency

          -  One or more symptom(s) of testosterone deficiency (i.e. fatigue, reduced libido, or
             reduced sexual functioning)

          -  Body mass index (BMI) between 18 and 35 kg/m^2

          -  All screening lab tests within 20% of the normal range (exceptions are liver function
             tests)

          -  HIV, Hepatitis B and C negative

        Exclusion Criteria:

          -  Previous use of FE 999303

          -  Prostate cancer

          -  Breast carcinoma, patient or partner

          -  Palpable prostatic mass(es)

          -  Serum PSA levels ≥3 ng/dL

          -  Chronic use of any drug of abuse

          -  Lower urinary tract obstruction

          -  Clinically significant anemia or renal dysfunction

          -  Cardiovascular disease

          -  Hyperparathyroidism or uncontrolled diabetes

          -  Generalized skin irritation or significant skin disease

          -  Use of any medications that could be considered anabolic (e.g. dehydroepiandrosterone
             (DHEA)) or could interfere with androgen metabolism (e.g. spironolactone,
             5-alfa-reductase-inhibitors, ketoconazole, abiraterone)

          -  Use of estrogens, GnRH agonists/antagonist, antiandrogens, human GH (within previous
             12 months of screening)

          -  Use of testosterone products (within 8 weeks of screening for parenteral products, or
             6 weeks of screening for other preparations)

          -  Sleep apnea

          -  Untreated depression

          -  Subject with a partner who is pregnant or will not use contraception
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AccuMed Research Associates</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2011</study_first_submitted>
  <study_first_submitted_qc>November 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2011</study_first_posted>
  <results_first_submitted>June 29, 2017</results_first_submitted>
  <results_first_submitted_qc>June 29, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 28, 2017</results_first_posted>
  <disposition_first_submitted>May 13, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>May 13, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 21, 2013</disposition_first_posted>
  <last_update_submitted>August 15, 2017</last_update_submitted>
  <last_update_submitted_qc>August 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at one study site in the US. Out of 78 subjects screened, 20 subjects were enrolled in the study.</recruitment_details>
      <pre_assignment_details>Apart from having history of hypogonadism, the study subjects were required to present with one or more symptoms of testosterone deficiency (i.e. fatigue, decreased muscle mass, reduced libido, reduced sexual functioning of a non-mechanical nature). The study subjects needed to be in good health despite exhibiting hypogonadism.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Testosterone Topical</title>
          <description>Initially subjects self-applied 2.50 mL (two strokes) of testosterone gel by hand every day for seven days followed by a 7-day washout period. After washout period, subjects sequentially self-applied ascending doses of testosterone gel with the applicator; 1.25 mL (one stroke), 2.50 mL (two strokes), and 3.75 mL (three strokes), respectively every day for seven days with no washout period in between.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Hand Application (2.50 mL)</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Washout Period</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Applicator Application (1.25 mL)</title>
              <participants_list>
                <participants group_id="P1" count="19">One subject discontinued due to non-compliance.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Applicator Application (2.50 mL)</title>
              <participants_list>
                <participants group_id="P1" count="18">One subject discontinued due to physician's decision.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Applicator Application (3.75 mL)</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The data are presented for Intent-to-treat (ITT) population, which comprised of all subjects who received at least one dose of the Investigational Medicinal Product (IMP).</population>
      <group_list>
        <group group_id="B1">
          <title>Testosterone Topical</title>
          <description>Initially study subjects self-applied 2.50 mL (two strokes) of testosterone gel by hand every day for seven days followed by a 7-day washout period. After washout period, study subjects sequentially self-applied ascending doses of testosterone gel with the applicator; 1.25 mL (one stroke), 2.50 mL (two strokes), and 3.75 mL (three strokes), respectively every day for seven days with no washout period in between.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.1" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>inch</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.2" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>lbs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="203.7" spread="29.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.8" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Responder Rate: Percentage of Subjects Whose Average Steady State Concentration (Cavg) of Serum Total Testosterone Levels Are Between 300 and 1050 ng/dL Following Treatment With Each of Three Volumes of FE 999303 Applied With an Applicator.</title>
        <description>Descriptive statistics was used to present the outcome results.</description>
        <time_frame>Days 15-21, Days 22-28 &amp; Days 29-35</time_frame>
        <population>Full Analysis Set (FAS) population was used for this analysis, which comprised of all subjects who had any available Pharmacokinetic (PK) data.</population>
        <group_list>
          <group group_id="O1">
            <title>Testosterone 1.25 mL (Applicator)</title>
            <description>Subjects in this arm self-applied one stroke (1.25 mL) of testosterone gel by applicator to the shoulder/upper arm everyday for seven days.</description>
          </group>
          <group group_id="O2">
            <title>Testosterone 2.50 mL (Applicator)</title>
            <description>Subjects in this arm self-applied two strokes (2.50 mL) of testosterone gel by applicator, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm everyday for seven days.</description>
          </group>
          <group group_id="O3">
            <title>Testosterone 3.75 mL (Applicator)</title>
            <description>Subjects in this arm self-applied three strokes (3.75 mL) of testosterone gel by applicator, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm and a third stroke to the first shoulder/upper arm, everyday for seven days.</description>
          </group>
        </group_list>
        <measure>
          <title>Responder Rate: Percentage of Subjects Whose Average Steady State Concentration (Cavg) of Serum Total Testosterone Levels Are Between 300 and 1050 ng/dL Following Treatment With Each of Three Volumes of FE 999303 Applied With an Applicator.</title>
          <description>Descriptive statistics was used to present the outcome results.</description>
          <population>Full Analysis Set (FAS) population was used for this analysis, which comprised of all subjects who had any available Pharmacokinetic (PK) data.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="77.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Responder Rate: Percentage of Subjects Whose Cavg Serum Total Testosterone Levels Are Between 300 and 1050 ng/dL Following Treatment With One Volume of FE 999303 Applied by Hand.</title>
        <time_frame>Days 1-7</time_frame>
        <population>FAS population was used for this analysis, which comprised of all subjects who had any available PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Testosterone 2.50 mL (Hand)</title>
            <description>Subjects in this arm self-applied two strokes (2.50 mL) of testosterone gel by hand, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm everyday for seven days.</description>
          </group>
        </group_list>
        <measure>
          <title>Responder Rate: Percentage of Subjects Whose Cavg Serum Total Testosterone Levels Are Between 300 and 1050 ng/dL Following Treatment With One Volume of FE 999303 Applied by Hand.</title>
          <population>FAS population was used for this analysis, which comprised of all subjects who had any available PK data.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of Total Testosterone and DHT (Dihydrotestosterone) Measuring Area Under the Concentration-time Curve From the Last Dose and 24 Hrs. Post Dose (AUCτ)</title>
        <time_frame>Samples were collected pre-dose and at 2, 4, 6, 8, 10, 12, and 24 hr post-dose on Day 21, Day 28 &amp; Day 35 of testosterone gel application through applicator</time_frame>
        <population>FAS population was used for this analysis, which comprised of all subjects who had any available PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Testosterone 1.25 mL (Applicator)</title>
            <description>Subjects in this arm self-applied one stroke (1.25 mL) of testosterone gel by applicator to the shoulder/upper arm everyday for seven days.</description>
          </group>
          <group group_id="O2">
            <title>Testosterone 2.50 mL (Applicator)</title>
            <description>Subjects in this arm self-applied two strokes (2.50 mL) of testosterone gel by applicator, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm everyday for seven days.</description>
          </group>
          <group group_id="O3">
            <title>Testosterone 3.75 mL (Applicator)</title>
            <description>Subjects in this arm self-applied three strokes (3.75 mL) of testosterone gel by applicator, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm and a third stroke to the first shoulder/upper arm, everyday for seven days.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of Total Testosterone and DHT (Dihydrotestosterone) Measuring Area Under the Concentration-time Curve From the Last Dose and 24 Hrs. Post Dose (AUCτ)</title>
          <population>FAS population was used for this analysis, which comprised of all subjects who had any available PK data.</population>
          <units>ng*hr/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Testosterone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5768" spread="1228"/>
                    <measurement group_id="O2" value="7686" spread="2648"/>
                    <measurement group_id="O3" value="10295" spread="3764"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DHT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="688" spread="349"/>
                    <measurement group_id="O2" value="974" spread="674"/>
                    <measurement group_id="O3" value="1223" spread="666"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of Total Testosterone and DHT Measuring Time of Maximum Observed Concentration (Tmax)</title>
        <time_frame>Samples were collected pre-dose and at 2, 4, 6, 8, 10, 12, and 24 hr post-dose on Day 21, Day 28 &amp; Day 35 of testosterone gel application through applicator</time_frame>
        <population>FAS population was used for this analysis, which comprised of all subjects who had any available PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Testosterone 1.25 mL (Applicator)</title>
            <description>Subjects in this arm self-applied one stroke (1.25 mL) of testosterone gel by applicator to the shoulder/upper arm everyday for seven days.</description>
          </group>
          <group group_id="O2">
            <title>Testosterone 2.50 mL (Applicator)</title>
            <description>Subjects in this arm self-applied two strokes (2.50 mL) of testosterone gel by applicator, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm everyday for seven days.</description>
          </group>
          <group group_id="O3">
            <title>Testosterone 3.75 mL (Applicator)</title>
            <description>Subjects in this arm self-applied three strokes (3.75 mL) of testosterone gel by applicator, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm and a third stroke to the first shoulder/upper arm, everyday for seven days.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of Total Testosterone and DHT Measuring Time of Maximum Observed Concentration (Tmax)</title>
          <population>FAS population was used for this analysis, which comprised of all subjects who had any available PK data.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Testosterone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.77" lower_limit="0.0" upper_limit="24.0"/>
                    <measurement group_id="O2" value="3.77" lower_limit="1.75" upper_limit="7.77"/>
                    <measurement group_id="O3" value="3.77" lower_limit="1.77" upper_limit="9.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DHT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.75" lower_limit="0.0" upper_limit="24.0"/>
                    <measurement group_id="O2" value="3.78" lower_limit="0.0" upper_limit="7.77"/>
                    <measurement group_id="O3" value="3.86" lower_limit="1.78" upper_limit="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of Total Testosterone and DHT Measuring Maximum Concentration Observed (Cmax)</title>
        <time_frame>Samples were collected pre-dose and at 2, 4, 6, 8, 10, 12, and 24 hr post-dose on Day 21, Day 28 &amp; Day 35 of testosterone gel application through applicator</time_frame>
        <population>FAS population was used for this analysis, which comprised of all subjects who had any available PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Testosterone 1.25 mL (Applicator)</title>
            <description>Subjects in this arm self-applied one stroke (1.25 mL) of testosterone gel by applicator to the shoulder/upper arm everyday for seven days.</description>
          </group>
          <group group_id="O2">
            <title>Testosterone 2.50 mL (Applicator)</title>
            <description>Subjects in this arm self-applied two strokes (2.50 mL) of testosterone gel by applicator, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm everyday for seven days.</description>
          </group>
          <group group_id="O3">
            <title>Testosterone 3.75 mL (Applicator)</title>
            <description>Subjects in this arm self-applied three strokes (3.75 mL) of testosterone gel by applicator, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm and a third stroke to the first shoulder/upper arm, everyday for seven days.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of Total Testosterone and DHT Measuring Maximum Concentration Observed (Cmax)</title>
          <population>FAS population was used for this analysis, which comprised of all subjects who had any available PK data.</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Testosterone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="396" spread="137"/>
                    <measurement group_id="O2" value="641" spread="319"/>
                    <measurement group_id="O3" value="1024" spread="700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DHT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.6" spread="20.3"/>
                    <measurement group_id="O2" value="57.7" spread="39.0"/>
                    <measurement group_id="O3" value="78.9" spread="58.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of Total Testosterone and DHT Measuring Cavg</title>
        <time_frame>Samples were collected pre-dose and at 2, 4, 6, 8, 10, 12, and 24 hr post-dose on Day 21, Day 28 &amp; Day 35 of testosterone gel application through applicator</time_frame>
        <population>FAS population was used for this analysis, which comprised of all subjects who had any available PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Testosterone 1.25 mL (Applicator)</title>
            <description>Subjects in this arm self-applied one stroke (1.25 mL) of testosterone gel by applicator to the shoulder/upper arm everyday for seven days.</description>
          </group>
          <group group_id="O2">
            <title>Testosterone 2.50 mL (Applicator)</title>
            <description>Subjects in this arm self-applied two strokes (2.50 mL) of testosterone gel by applicator, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm everyday for seven days.</description>
          </group>
          <group group_id="O3">
            <title>Testosterone 3.75 mL (Applicator)</title>
            <description>Subjects in this arm self-applied three strokes (3.75 mL) of testosterone gel by applicator, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm and a third stroke to the first shoulder/upper arm, everyday for seven days.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of Total Testosterone and DHT Measuring Cavg</title>
          <population>FAS population was used for this analysis, which comprised of all subjects who had any available PK data.</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Testosterone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240" spread="51"/>
                    <measurement group_id="O2" value="320" spread="110"/>
                    <measurement group_id="O3" value="429" spread="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DHT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.7" spread="14.5"/>
                    <measurement group_id="O2" value="40.6" spread="28.2"/>
                    <measurement group_id="O3" value="51.0" spread="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of Total Testosterone and DHT Measuring Minimum Concentration Observed (Cmin)</title>
        <time_frame>Samples were collected pre-dose and at 2, 4, 6, 8, 10, 12, and 24 hr post-dose on Day 21, Day 28 &amp; Day 35 of testosterone gel application through applicator</time_frame>
        <population>FAS population was used for this analysis, which comprised of all subjects who had any available PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Testosterone 1.25 mL (Applicator)</title>
            <description>Subjects in this arm self-applied one stroke (1.25 mL) of testosterone gel by applicator to the shoulder/upper arm everyday for seven days.</description>
          </group>
          <group group_id="O2">
            <title>Testosterone 2.50 mL (Applicator)</title>
            <description>Subjects in this arm self-applied two strokes (2.50 mL) of testosterone gel by applicator, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm everyday for seven days.</description>
          </group>
          <group group_id="O3">
            <title>Testosterone 3.75 mL (Applicator)</title>
            <description>Subjects in this arm self-applied three strokes (3.75 mL) of testosterone gel by applicator, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm and a third stroke to the first shoulder/upper arm, everyday for seven days.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of Total Testosterone and DHT Measuring Minimum Concentration Observed (Cmin)</title>
          <population>FAS population was used for this analysis, which comprised of all subjects who had any available PK data.</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Testosterone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173" spread="47"/>
                    <measurement group_id="O2" value="213" spread="69"/>
                    <measurement group_id="O3" value="250" spread="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DHT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1" spread="9.0"/>
                    <measurement group_id="O2" value="29.9" spread="21.9"/>
                    <measurement group_id="O3" value="37.3" spread="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of Total Testosterone and DHT Measuring Time of Minimum Observed Concentration (Tmin)</title>
        <time_frame>Samples were collected pre-dose and at 2, 4, 6, 8, 10, 12, and 24 hr post-dose on Day 21, Day 28 &amp; Day 35 of testosterone gel application through applicator</time_frame>
        <population>FAS population was used for this analysis, which comprised of all subjects who had any available PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Testosterone 1.25 mL (Applicator)</title>
            <description>Subjects in this arm self-applied one stroke (1.25 mL) of testosterone gel by applicator to the shoulder/upper arm everyday for seven days.</description>
          </group>
          <group group_id="O2">
            <title>Testosterone 2.50 mL (Applicator)</title>
            <description>Subjects in this arm self-applied two strokes (2.50 mL) of testosterone gel by applicator, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm everyday for seven days.</description>
          </group>
          <group group_id="O3">
            <title>Testosterone 3.75 mL (Applicator)</title>
            <description>Subjects in this arm self-applied three strokes (3.75 mL) of testosterone gel by applicator, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm and a third stroke to the first shoulder/upper arm, everyday for seven days.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of Total Testosterone and DHT Measuring Time of Minimum Observed Concentration (Tmin)</title>
          <population>FAS population was used for this analysis, which comprised of all subjects who had any available PK data.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Testosterone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.78" lower_limit="0.0" upper_limit="24.0"/>
                    <measurement group_id="O2" value="10.81" lower_limit="0.0" upper_limit="24.0"/>
                    <measurement group_id="O3" value="4.76" lower_limit="0.0" upper_limit="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DHT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.83" lower_limit="0.0" upper_limit="11.8"/>
                    <measurement group_id="O2" value="11.0" lower_limit="0.0" upper_limit="24.0"/>
                    <measurement group_id="O3" value="9.79" lower_limit="0.0" upper_limit="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of Total Testosterone and DHT Measuring AUCτ</title>
        <time_frame>Samples were collected pre-dose and at 2, 4, 6, 8, 10, 12, and 24 hr post-dose on Day 7 of testosterone gel application through hand</time_frame>
        <population>FAS population was used for this analysis, which comprised of all subjects who had any available PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Testosterone 2.50 mL (Hand)</title>
            <description>Subjects in this arm self-applied two strokes (2.50 mL) of testosterone gel by hand, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm everyday for seven days.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of Total Testosterone and DHT Measuring AUCτ</title>
          <population>FAS population was used for this analysis, which comprised of all subjects who had any available PK data.</population>
          <units>ng*hr/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Testosterone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7809" spread="2609"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DHT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1143" spread="740"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of Total Testosterone and DHT Measuring Tmax</title>
        <time_frame>Samples were collected pre-dose and at 2, 4, 6, 8, 10, 12, and 24 hr post-dose on Day 7 of testosterone gel application through hand</time_frame>
        <population>FAS population was used for this analysis, which comprised of all subjects who had any available PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Testosterone 2.50 mL (Hand)</title>
            <description>Subjects in this arm self-applied two strokes (2.50 mL) of testosterone gel by hand, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm everyday for seven days.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of Total Testosterone and DHT Measuring Tmax</title>
          <population>FAS population was used for this analysis, which comprised of all subjects who had any available PK data.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Testosterone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.86" lower_limit="0.0" upper_limit="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DHT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.86" lower_limit="0.0" upper_limit="7.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of Total Testosterone and DHT Measuring Cmax</title>
        <time_frame>Samples were collected pre-dose and at 2, 4, 6, 8, 10, 12, and 24 hr post-dose on Day 7 of testosterone gel application through hand</time_frame>
        <population>FAS population was used for this analysis, which comprised of all subjects who had any available PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Testosterone 2.50 mL (Hand)</title>
            <description>Subjects in this arm self-applied two strokes (2.50 mL) of testosterone gel by hand, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm everyday for seven days.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of Total Testosterone and DHT Measuring Cmax</title>
          <population>FAS population was used for this analysis, which comprised of all subjects who had any available PK data.</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Testosterone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="517" spread="381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DHT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.1" spread="58.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of Total Testosterone and DHT Measuring Cavg</title>
        <time_frame>Samples were collected pre-dose and at 2, 4, 6, 8, 10, 12, and 24 hr post-dose on Day 7 of testosterone gel application through hand</time_frame>
        <population>FAS population was used for this analysis, which comprised of all subjects who had any available PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Testosterone 2.50 mL (Hand)</title>
            <description>Subjects in this arm self-applied two strokes (2.50 mL) of testosterone gel by hand, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm everyday for seven days.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of Total Testosterone and DHT Measuring Cavg</title>
          <population>FAS population was used for this analysis, which comprised of all subjects who had any available PK data.</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Testosterone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="325" spread="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DHT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.6" spread="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of Total Testosterone and DHT Measuring Cmin</title>
        <time_frame>Samples were collected pre-dose and at 2, 4, 6, 8, 10, 12, and 24 hr post-dose on Day 7 of testosterone gel application through hand</time_frame>
        <population>FAS population was used for this analysis, which comprised of all subjects who had any available PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Testosterone 2.50 mL (Hand)</title>
            <description>Subjects in this arm self-applied two strokes (2.50 mL) of testosterone gel by hand, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm everyday for seven days.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of Total Testosterone and DHT Measuring Cmin</title>
          <population>FAS population was used for this analysis, which comprised of all subjects who had any available PK data.</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Testosterone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="234" spread="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DHT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.4" spread="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of Total Testosterone and DHT Measuring Tmin</title>
        <time_frame>Samples were collected pre-dose and at 2, 4, 6, 8, 10, 12, and 24 hr post-dose on Day 7 of testosterone gel application through hand</time_frame>
        <population>FAS population was used for this analysis, which comprised of all subjects who had any available PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Testosterone 2.50 mL (Hand)</title>
            <description>Subjects in this arm self-applied two strokes (2.50 mL) of testosterone gel by hand, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm everyday for seven days.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of Total Testosterone and DHT Measuring Tmin</title>
          <population>FAS population was used for this analysis, which comprised of all subjects who had any available PK data.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Testosterone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.84" lower_limit="0.0" upper_limit="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DHT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" lower_limit="0.0" upper_limit="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Overall Treatment Period (36 Days)</time_frame>
      <desc>Adverse events with onset after start of the first IMP administration were considered treatment-emergent and are presented.</desc>
      <group_list>
        <group group_id="E1">
          <title>Testosterone 2.50 mL (Hand)</title>
          <description>Subjects in this arm self-applied two strokes (2.50 mL) of testosterone gel by hand, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm everyday for seven days.</description>
        </group>
        <group group_id="E2">
          <title>Testosterone 1.25 mL (Applicator)</title>
          <description>Subjects in this arm self-applied one stroke (1.25 mL) of testosterone gel by applicator to the shoulder/upper arm everyday for seven days.</description>
        </group>
        <group group_id="E3">
          <title>Testosterone 2.50 mL (Applicator)</title>
          <description>Subjects in this arm self-applied two strokes (2.50 mL) of testosterone gel by applicator, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm everyday for seven days.</description>
        </group>
        <group group_id="E4">
          <title>Testosterone 3.75 mL (Applicator)</title>
          <description>Subjects in this arm self-applied three strokes (3.75 mL) of testosterone gel by applicator, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm and a third stroke to the first shoulder/upper arm, everyday for seven days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is a restriction on joint publications prepared in collaboration between investigator and sponsor as Ferring reserves the right to be involved in this decision. In the event of any disagreement in the content of any publication both investigator’s and Ferring´s opinion will be fairly and sufficiently represented in the publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Development Support</name_or_title>
      <organization>Ferring Pharmaceuticals</organization>
      <email>DK0-Disclosure@ferring.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

